These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Effect of high doses of magnesium on converting ibutilide to a safe and more effective agent. Patsilinakos S; Christou A; Kafkas N; Nikolaou N; Antonatos D; Katsanos S; Spanodimos S; Babalis D Am J Cardiol; 2010 Sep; 106(5):673-6. PubMed ID: 20723644 [TBL] [Abstract][Full Text] [Related]
6. Female gender does not influence the magnitude of ibutilide-induced repolarization delay and incidence of torsades de pointes in an in vivo rabbit model of the acquired long QT syndrome. Johansson M; Carlsson L J Cardiovasc Pharmacol Ther; 2001 Jul; 6(3):247-54. PubMed ID: 11584331 [TBL] [Abstract][Full Text] [Related]
7. Ibutilide (Corvert): suspected association with torsades de pointes. CMAJ; 2004 Oct; 171(8):994. PubMed ID: 15497210 [No Abstract] [Full Text] [Related]
8. Pharmacokinetics of ibutilide in patients with heart failure due to left ventricular systolic dysfunction. Tisdale JE; Overholser BR; Sowinski KM; Wroblewski HA; Amankwa K; Borzak S; Kingery JR; Coram R; Zipes DP; Flockhart DA; Kovacs RJ Pharmacotherapy; 2008 Dec; 28(12):1461-70. PubMed ID: 19025427 [TBL] [Abstract][Full Text] [Related]
9. Safety and risk/benefit analysis of ibutilide for acute conversion of atrial fibrillation/flutter. Kowey PR; VanderLugt JT; Luderer JR Am J Cardiol; 1996 Oct; 78(8A):46-52. PubMed ID: 8903276 [TBL] [Abstract][Full Text] [Related]
10. Dofetilide-induced long QT and torsades de pointes. Aktas MK; Shah AH; Akiyama T Ann Noninvasive Electrocardiol; 2007 Jul; 12(3):197-202. PubMed ID: 17617063 [TBL] [Abstract][Full Text] [Related]
11. Electrophysiology and pharmacology of ibutilide. Naccarelli GV; Lee KS; Gibson JK; VanderLugt J Am J Cardiol; 1996 Oct; 78(8A):12-6. PubMed ID: 8903270 [TBL] [Abstract][Full Text] [Related]
12. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. Torp-Pedersen C; Møller M; Bloch-Thomsen PE; Køber L; Sandøe E; Egstrup K; Agner E; Carlsen J; Videbaek J; Marchant B; Camm AJ N Engl J Med; 1999 Sep; 341(12):857-65. PubMed ID: 10486417 [TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of ibutilide in cardioversion of atrial flutter and fibrillation. Nair M; George LK; Koshy SK J Am Board Fam Med; 2011; 24(1):86-92. PubMed ID: 21209348 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of ibutilide for the conversion of monomorphic atrial tachycardia. Eidher U; Freihoff F; Kaltenbrunner W; Steinbach K Pacing Clin Electrophysiol; 2006 Apr; 29(4):358-62. PubMed ID: 16650262 [TBL] [Abstract][Full Text] [Related]
15. Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents. Hongo RH; Themistoclakis S; Raviele A; Bonso A; Rossillo A; Glatter KA; Yang Y; Scheinman MM J Am Coll Cardiol; 2004 Aug; 44(4):864-8. PubMed ID: 15312873 [TBL] [Abstract][Full Text] [Related]
16. Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs. Singh BN; Wadhani N J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S85-97. PubMed ID: 15378133 [TBL] [Abstract][Full Text] [Related]
17. Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes. Shah SA; Kluger J; White CM Pharmacotherapy; 2007 Sep; 27(9):1297-305. PubMed ID: 17723083 [TBL] [Abstract][Full Text] [Related]
18. The role of amiodarone in recent-onset atrial fibrillation after ibutilide has failed to restore sinus rhythm. Sideris S; Bonios M; Melexopoulou C; Exarchos P; Tsatiris K; Kogias J Cardiology; 2007; 107(4):399-401. PubMed ID: 17284902 [TBL] [Abstract][Full Text] [Related]
19. Comparative assessment of ibutilide, D-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia. Buchanan LV; Kabell G; Brunden MN; Gibson JK J Cardiovasc Pharmacol; 1993 Oct; 22(4):540-9. PubMed ID: 7505355 [TBL] [Abstract][Full Text] [Related]
20. Dofetilide: a new class III antiarrhythmic agent. Roukoz H; Saliba W Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):9-19. PubMed ID: 17187453 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]